Prescient Therapeutics (ASX:PTX) launched a share purchase plan (SPP) to raise up to AU$7 million, with new fully paid ordinary shares to be issued at AU$0.065 per share, according to a Tuesday Australian bourse filing.
The company said the issue price represents an 18.8% discount to the volume-weighted average price over the 10 trading days before the SPP was disclosed and a 9.7% discount to the last price.
The company's shares fell 7% in recent Tuesday trade.